Multi component vaccine containing clostridial and non-clostridial organisms in a low dose

Abstract

Disclosed herein is a multicomponent low dose vaccine comprising a safe and immunogenically effective combination of a protective antigen component or components of clostridial organism, a protective antigen component of a non-clostridial organism and an adjuvant.

1 - 45 . (canceled) 
   
   
       46 . A method for reducing injection site lesion formation by at least 41% when immunizing cattle using an encapsulating polymer adjuvant in a multicomponent vaccine comprising an immunogenically effective combination of protective antigen components from at least six clostridial organisms, a protective antigen component from  Moraxella Bovis  ( M.Bovis ), and an encapsulating polymer adjuvant, comprising administering the multicomponent vaccine in a dose size of about 2 ml., thereby reducing injection site lesion formation by at least 41% compared with conventional injection of 5 ml of vaccine and accomplishing effective immunization. 
   
   
       47 . A method for reducing injection site lesion formation by at least 41% when immunizing cattle using an encapsulating polymer adjuvant in a multicomponent vaccine comprising an immunogenically effective combination of protective antigen components from seven clostridial organisms, a protective antigen component from  M.Bovis,  and an encapsulating polymer adjuvant, comprising administering the multicomponent vaccine in a dose size of about 2 ml., thereby reducing injection site lesion formation by at least 41% compared with conventional injection of 5 ml of said vaccine and accomplishing effective immunization. 
   
   
       48 . (canceled) 
   
   
       49 . The method of  claim 46 , wherein the protective antigen components from clostridial organisms are selected from the group consisting of  Cl. chauvoei, Cl. septicum, Cl novyi, Cl. perfringens  type C,  Cl. perfringens  type D,  Cl. sordellii, Cl. tetani  and  Cl. haemolyticum.    
   
   
       50 . The method of  claim 46 , wherein each of the protective antigen components is adjuvanated separately, thereby encapsulating each component separately and causing each to be released slowly over a period of several weeks after administration. 
   
   
       51 . The method of  claim 46 , wherein the multicomponent vaccine is administered intramuscularly.